What does this research mean for the field?

Long-term inhibition of endothelial nitric oxide synthesis increases arterial thrombogenicity, at least in part, through angiotensin II-induced induction of tissue factor and subsequent thrombin generation. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to investigate how long-term inhibition of nitric oxide synthesis affects arterial thrombogenecity.

April 1, 2002AJP Heart and Circulatory Physiology

Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery

View Full Paper

Ask AI

Bookmark

Why the study?

Does ACE inhibition or thrombin antagonism prevent L-NAME-induced arterial thrombogenicity in rats?

Population

Rats with stenosis of the carotid artery treated with N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 weeks

Comparison

ACE inhibitor, thrombin antagonist, or hydralazine vs L-NAME alone or L-NAME plus hydralazine

Design

Preclinical

Follow-up

4 weeks

Authors

MKMayuko Kubo-InoueKyushu University KEKensuke EgashiraKyushu University MUMakoto UsuiPanasonic (Japan)

Discussion

Member takes

Implication

Supports ACE-specific antithrombotic effects in NO-deficient rat models; hypothesis-generating, leaves human translation open.

Key Points

The aim is to investigate how long-term inhibition of nitric oxide synthesis affects arterial thrombogenecity.
Rats were treated with N(G)-nitro-L-arginine methyl ester (L-NAME) to inhibit nitric oxide synthesis for 4 weeks.
Observations of cyclic flow variations (CFVs) were recorded to assess thrombi formation.
The effects of treatment with angiotensin-converting enzyme (ACE) inhibitors and hydralazine on thrombus formation were compared.
Cyclic flow variations indicative of thrombi were observed in L-NAME treated rats (event rate not quantified).
ACE inhibitor imidapril prevented increases in carotid arterial ACE activity and reduced tissue factor expression, contrasting with effects of hydralazine.
The thrombin antagonist argatroban effectively suppressed CFVs, indicating a role for thrombin in thrombogenecity.

Structured PICO

Does ACE inhibition or thrombin antagonism prevent L-NAME-induced arterial thrombogenicity in rats?

Population

Rats with stenosis of the carotid artery treated with N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 weeks

Intervention

ACE inhibitor (imidapril), thrombin antagonist (argatroban), or hydralazine

Comparator

L-NAME alone or L-NAME plus hydralazine

Outcome

Cyclic flow variations (CFVs), carotid arterial ACE activity, and tissue factor expressionsurrogate

Long-term inhibition of endothelial NO synthesis increases arterial thrombogenicity via angiotensin II-induced tissue factor expression, which can be prevented by ACE inhibition.

Cite This Study

Kubo-Inoue et al. (2002) studied this question.

synapsesocial.com/papers/6a1bc2dd69a4af5b15a8f3b0 https://doi.org/10.1152/ajpheart.00739.2001

View Full Paper

Ask AI

Bookmark

Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider